Abstract
Chronic kidney disease (CKD) is a global public health problem. Currently, as for advanced CKD populations, medication options limited in angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB), which were partially effective. A Chinese herbal compound, Bupi Yishen formula, has showed renal protective potential in experiments and retrospective studies. This study will evaluate the efficacy and safety of Bupi Yishen formula (BYF) in patients with CKD stage 4. In this double blind, double dummy, randomized controlled trial (RCT), there will be 554 non-diabetes stage 4 CKD patients from 16 hospitals included and randomized into two groups: Chinese medicine (CM) group or losartan group. All patients will receive basic conventional therapy. Patients in CM group will be treated with BYF daily while patients in control group will receive losartan 100 mg daily for one year. The primary outcome is the change in estimated glomerular filtration rate (eGFR) over 12 months. Secondary outcomes include the incidence of endpoint events, liver and kidney function, urinary protein creatinine ratio, cardiovascular function and quality of life. This study will be the first multi-center, double blind RCT to assess wh...Continue Reading
References
Sep 18, 1997·Lancet·B K Krämer, F Schweda
Jun 5, 2003·Pediatrics·Ronald J HoggUNKNOWN National Kidney Foundation's Kidney Disease Outcomes Quality Initiative
Jul 17, 2003·Kidney International. Supplement·Janice G Douglas, Lawrence Agodoa
Jul 6, 2004·Journal of Ethnopharmacology·T B NgH X Wang
Apr 6, 2005·Life Sciences·Haiyan JinKiwamu Okita
Jan 13, 2006·The New England Journal of Medicine·Fan Fan HouRen Wen Geng
Nov 9, 2006·Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine·UNKNOWN Chinese Association of Integrative Medicine, Liver Disease Committee
Dec 13, 2006·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Andrew S LeveyJoel D Kopple
Jan 11, 2007·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·LuXia ZhangHaiYan Wang
Apr 10, 2007·Journal of Ethnopharmacology·Yong Gyu LeeJae Youl Cho
May 15, 2007·Journal of the American Society of Nephrology : JASN·Fan Fan HouJian Ping Jiang
Nov 8, 2007·JAMA : the Journal of the American Medical Association·Josef CoreshAndrew S Levey
Apr 4, 2008·American Journal of Epidemiology·Brad C AstorJosef Coresh
Jul 22, 2008·International Journal of Biological Macromolecules·Sun Yongxu, Liu Jicheng
Nov 8, 2008·Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine·Yong-jun WangChong-jian Zhou
May 13, 2009·Journal of Zhejiang University. Science. B·Chuan ZuoJun-ming Fan
Jun 25, 2009·Chemistry & Biodiversity·Yong-Xu Sun
Nov 17, 2009·Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine·Guan-jun PuLi-qun He
Jan 8, 2010·The New England Journal of Medicine·Hanna Abboud, William L Henrich
May 26, 2010·Clinical Journal of the American Society of Nephrology : CJASN·Faruk TurgutEmaad M Abdel-Rahman
Jul 28, 2010·Journal of Ethnopharmacology·Feixia DongLiqun He
Oct 19, 2010·Journal of Ethnopharmacology·Mingxin LiShanyan Lin
Oct 15, 2011·PloS One·Lizhen TaoJianzong Chen
Dec 20, 2011·Journal of Ethnopharmacology·Yong-jun WangXusheng Liu
May 17, 2012·Circulation. Heart Failure·Lesley A InkerAndrew S Levey
Dec 4, 2013·Journal of Ethnopharmacology·Chun-Mei Yao, Xiu-Wei Yang
Jan 29, 2014·The American Journal of Chinese Medicine·Jung-Chun LiaoWen-Huang Peng
Apr 3, 2014·PloS One·Junjie GaoShuyi Cao
Jun 3, 2014·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Guo-Jun ZhouTong-Shui Zhou
Citations
Jun 14, 2018·Experimental and Therapeutic Medicine·Haiyan Guo, Linyun Zhang
Jun 26, 2018·Frontiers in Pharmacology·Jing ZhangXiao-Hui Qiu
Nov 9, 2020·Natural Products and Bioprospecting·Christian Bailly
Mar 13, 2021·Frontiers in Pharmacology·Wei MaoXusheng Liu
Aug 12, 2021·BMC Complementary Medicine and Therapies·Yenan MoXusheng Liu